These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 19420129)

  • 1. Semiphysiologically based pharmacokinetic models for the inhibition of midazolam clearance by diltiazem and its major metabolite.
    Zhang X; Quinney SK; Gorski JC; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Aug; 37(8):1587-97. PubMed ID: 19420129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Study Design Using Continuous Intravenous and Intraduodenal Infusions of Midazolam and Voriconazole for Mechanistic Quantitative Assessment of Hepatic and Intestinal CYP3A Inhibition.
    Li X; Junge L; Taubert M; von Georg A; Dahlinger D; Starke C; Frechen S; Stelzer C; Kinzig M; Sörgel F; Jaehde U; Töx U; Goeser T; Fuhr U
    J Clin Pharmacol; 2020 Sep; 60(9):1237-1253. PubMed ID: 32427354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates.
    Fenneteau F; Poulin P; Nekka F
    J Pharm Sci; 2010 Jan; 99(1):486-514. PubMed ID: 19479982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of midazolam-CYP3A inhibitors interaction in the human liver from in vivo/in vitro absorption, distribution, and metabolism data.
    Yamano K; Yamamoto K; Katashima M; Kotaki H; Takedomi S; Matsuo H; Ohtani H; Sawada Y; Iga T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):443-52. PubMed ID: 11259329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin.
    Quinney SK; Zhang X; Lucksiri A; Gorski JC; Li L; Hall SD
    Drug Metab Dispos; 2010 Feb; 38(2):241-8. PubMed ID: 19884323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of the effect of erythromycin, diltiazem, and their metabolites, alone and in combination, on CYP3A4 inhibition.
    Zhang X; Jones DR; Hall SD
    Drug Metab Dispos; 2009 Jan; 37(1):150-60. PubMed ID: 18854379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results.
    Chenel M; Bouzom F; Cazade F; Ogungbenro K; Aarons L; Mentré F
    J Pharmacokinet Pharmacodyn; 2008 Dec; 35(6):661-81. PubMed ID: 19130187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models.
    Vossen M; Sevestre M; Niederalt C; Jang IJ; Willmann S; Edginton AN
    Theor Biol Med Model; 2007 Mar; 4():13. PubMed ID: 17386084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies.
    Prueksaritanont T; Kuo Y; Tang C; Li C; Qiu Y; Lu B; Strong-Basalyga K; Richards K; Carr B; Lin JH
    Drug Metab Dispos; 2006 Sep; 34(9):1546-55. PubMed ID: 16782766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats.
    Lai L; Hao H; Wang Q; Zheng C; Zhou F; Liu Y; Wang Y; Yu G; Kang A; Peng Y; Wang G; Chen X
    Drug Metab Dispos; 2009 Dec; 37(12):2399-407. PubMed ID: 19741040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stochastic prediction of CYP3A-mediated inhibition of midazolam clearance by ketoconazole.
    Chien JY; Lucksiri A; Ernest CS; Gorski JC; Wrighton SA; Hall SD
    Drug Metab Dispos; 2006 Jul; 34(7):1208-19. PubMed ID: 16611859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of CYP3A by erythromycin: in vitro-in vivo correlation in rats.
    Zhang X; Galinsky RE; Kimura RE; Quinney SK; Jones DR; Hall SD
    Drug Metab Dispos; 2010 Jan; 38(1):61-72. PubMed ID: 19797607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of crizotinib-midazolam interaction using the Simcyp population-based simulator: comparison of CYP3A time-dependent inhibition between human liver microsomes versus hepatocytes.
    Mao J; Johnson TR; Shen Z; Yamazaki S
    Drug Metab Dispos; 2013 Feb; 41(2):343-52. PubMed ID: 23129213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation.
    Jones DR; Gorski JC; Hamman MA; Mayhew BS; Rider S; Hall SD
    J Pharmacol Exp Ther; 1999 Sep; 290(3):1116-25. PubMed ID: 10454485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-drug interactions and metabolism in cytochrome P450 2C knockout mice: application to troleandomycin and midazolam.
    Grimsley A; Gallagher R; Hutchison M; Pickup K; Wilson ID; Samuelsson K
    Biochem Pharmacol; 2013 Aug; 86(4):529-38. PubMed ID: 23732297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction.
    Fahmi OA; Hurst S; Plowchalk D; Cook J; Guo F; Youdim K; Dickins M; Phipps A; Darekar A; Hyland R; Obach RS
    Drug Metab Dispos; 2009 Aug; 37(8):1658-66. PubMed ID: 19406954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory Effect of Oxethazaine on Midazolam Metabolism in Rats.
    Namba H; Nishimura Y; Kurata N; Iwase M; Hirai T; Kiuchi Y
    Biol Pharm Bull; 2017; 40(9):1361-1365. PubMed ID: 28867721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
    Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
    Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo CYP3A4 activity does not predict the magnitude of interaction between itraconazole and tacrolimus from an extended release formulation.
    Vanhove T; Annaert P; Knops N; de Loor H; de Hoon J; Kuypers DRJ
    Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):50-55. PubMed ID: 29989304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
    Granvil CP; Yu AM; Elizondo G; Akiyama TE; Cheung C; Feigenbaum L; Krausz KW; Gonzalez FJ
    Drug Metab Dispos; 2003 May; 31(5):548-58. PubMed ID: 12695342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.